Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls.

Autor: Jansen, Valérie LBI, Davids, Mark, van Mourik, Dagmar JM, Levels, Johannes HM, Coppens, Michiel, Middeldorp, Saskia, Nieuwdorp, Max, van Mens, Thijs E
Předmět:
Zdroj: Lupus; Oct2024, Vol. 33 Issue 12, p1373-1378, 6p
Abstrakt: Introduction: The gut microbiome is recognized as a factor that could potentially contribute to the persistent antibodies of antiphospholipid syndrome (APS). Gut microbial interventions can both induce and mitigate APS in mice. In human APS patients, anti-beta-2-glycoprotein I (β2GP-1) titers correlate with antibody titers against a gut commensal protein homologous to β2GP-1. Aim: To investigate the effect of the intestinal microenvironment on human APS. Methods We cross-sectionally compared intestinal microbiota composition quantified by shotgun sequencing; fecal short chain fatty acids (SCFAs), bacterial metabolites known to affect autoimmune processes; and fecal calprotectin, an intestinal inflammatory marker, in APS patients and healthy controls. Results: Neither alpha nor beta diversity of the gut microbiota differed between APS patients (n = 15) and controls (n = 16) and no taxa were differentially abundant. Moreover, fecal SCFAs and fecal calprotectin, did not differ between the groups. Conclusion: Gut microbiome effects on the APS phenotype are likely not driven by bacterial overabundance, SCFA production or intestinal inflammation. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje